DXVX

180400KOSDAQ

44.5 / 100

Reference Date: 2026-09-08

Financial Score11.5 / 40

News Sentiment19.0 / 25

Momentum2.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 17.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

DXVX is a biopharmaceutical company specializing in medical diagnostics, healthcare, and drug development, expanding globally through the 2022 acquisition of Hanbio Pharm and the 2023 establishment of a Chinese subsidiary. In medical diagnostics, it leverages NGS and AI-based platforms with GMP-certified facilities, while its drug development focuses on oncology therapies through partnerships with Stanford University and the acquisition of Evexis Gen. The company plans to mitigate financial risks by licensing technologies to major pharmaceutical firms.

Number of Employees

62people

Average Salary

107.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.33Industry Average 1.201.0Point

1.9x industry avg (risky)

ROE

-52.77Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

39.00Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼20.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼45.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -123.0% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 4Neutral 1Negative 0Average Sentiment Score 76

Positive
DXVX "내년 상반기 범용 암백신 'OVM-200' 임상 2상 진입 ...
DXVX announces promising progress with universal cancer vaccine OVM-200 entering clinical trials, highlighting potential market expansion.
Neutral
한미약품 장남 최대주주 DXVX, 신임 대표 알고 보니 '그때 그 검사...
The news focuses on personal connections rather than direct financial impacts on DXVX.
Positive
DXVX "mRNA 면역항암제·KRNA '투트랙 개발'…기술 경쟁력 확...
DXVX announces advanced 'two-track' strategy leveraging mRNA technology for immune cancer therapy and nucleic acid stabilization, enhancing overall technological competitiveness.

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 2,265Won52-week high 5,11052-week low 1,653

1-month return0.0Point

1m -17.34% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

9 totalPositive 1Neutral 8Negative 0

Neutral주주명부폐쇄기간또는기준일설정2026-08-24
Neutral주주총회소집결의 (임시주주총회)2026-08-24
Neutral주식등의대량보유상황보고서(일반)2026-08-21
Positive[기재정정]단일판매ㆍ공급계약체결2026-08-21
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-21